Market Newsdesk

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sportradar Group AG (NASDAQ:SRAD) for potential securities fraud after its significant stock drop.

If you invested in Sportradar, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/sportradar-class-action.

Key Details of the Sportradar ($SRAD) Class Action Investigation:

• Investigation Overview: Securities fraud relating to allegations that Sportradar aided and abetted illegal gambling and derived a substantial portion of its revenue from such activities
• Stock Decline: April 22, 2026 – 22% Stock Drop
• Action: Contact BFA Law to discuss your rights

Why is Sportradar Being Investigated for Securities Fraud?

Sportradar is a global sports data and technology company that collects, analyzes, and distributes real-time sports data and insights to betting operators, leagues, media companies, and teams. Sportradar has partnerships with top leagues such as the NBA, MLB, NHL, and PGA Tour.

During the relevant period, Sportradar stated that “Integrity is key” and “at the heart of what we do.” Sportradar also compared itself to the FBI of gambling and stated that it monitors illegal market activity “very closely.”

BFA is investigating allegations that Sportradar actively aided and abetted illegal gambling across the world’s black and grey markets, and that it derived a substantial portion of its revenue from such activities.

Why did Sportradar’s Stock Drop?

On April 22, 2026, Muddy Waters, an investigative research firm, published a report titled “Sportradar AG: Putting the BET into Aiding and Abetting. The Leader of Sports Integrity Powers the World’s Illegal Online Sports Books.” The report revealed, among other things, that Sportradar’s business model “depends on illegal operators to survive.” Muddy Waters stated that Sportradar “has actively aided and abetted illegal gambling across the world’s black and grey markets — not as an accident or an oversight, but as a business strategy.” The report estimated that illegal operators contributed to about 20–40% of the company’s total revenues. What’s more, based on its proprietary research methods and extensive interviews with former employees, Muddy Waters identified nearly 50 Sportradar clients and collaborators who were operating in illegal markets.

The same day, Callisto Research, an investigative research firm, published a report titled “Sportradar Group AG: the ‘integrity’ giant threatening its own existence with ties to illegal gambling, sanctioned parties and criminals.” The report revealed, based on an examination of hundreds of gambling platforms, evidence suggesting that one-third of platforms Sportradar claims to serve were using Sportradar’s products or services, or explicitly claiming to do so, while operating illegally in regulated or prohibited gambling markets. Callisto Research revealed that exposure to unlicensed operators could be as high as 30-40% of Sportradar’s revenue. The report also revealed that three U.S. gambling regulators have already commenced reviews into the company.

This news caused the price of Sportradar stock to decline $3.80 per share, or 22.6%, from $16.84 per share on April 21, 2026, to $13.04 per share on April 22, 2026.

Click here for more information:


https://www.bfalaw.com/cases/sportradar-class-action


.

What Can You Do?

If you invested in Sportradar, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/sportradar-class-action

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/sportradar-class-action

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Willis Lease Finance Corporation’s (NASDAQ: WLFC) board of directors as well as executive chairman Charles F. Willis, IV (as the controlling shareholder) for potential breaches of their fiduciary duties to shareholders in connection with WLFC’s past and ongoing practices of paying potentially excessive compensation to Mr. Willis.

If you are a current shareholder of Willis Lease Finance, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/willis-lease-investigation

Why is Willis Lease Finance being Investigated?

Willis Lease is “effectively controlled” by Charles F. Willis, IV, who founded the company in 1985 and owns approximately 40% of the company’s stock. Willis Lease’s board of directors consists of Mr. Willis, his son (who serves as the CEO of Willis Lease), and three additional directors (who are purportedly independent and constitute the Company’s compensation committee).

In fiscal year 2022, Mr. Willis received compensation totaling approximately $6.2 million. In fiscal year 2023, he received compensation totaling approximately $10.7 million. In fiscal year 2024, he received compensation totally approximately $14.0 million. In fiscal year 2025, he received compensation totaling approximately $14.2 million. Over half of Mr. Willis’ total compensation for these years has been in the form of stock awards.

In 2024, the Company’s board of directors issued additional “one-time performance” stock awards to the Company’s executives, including an unexplained double-issuance of stock options worth $23.9 million to Mr. Willis.

Despite this substantial compensation, on November 10, 2025, Willis Lease’s compensation committee awarded Mr. Willis an option grant to purchase up to 300,000 shares of Willis Lease common stock “intended to retain and incentivize Mr. Willis to continue in the role of Executive Chairman” with a four-year vesting period and an exercise price linked to Willis Lease’s stock price at the time of the option grant. In the months following this option grant, Willis Lease’s stock price has risen significantly, giving the options significant value to Mr. Willis.

BFA is investigating whether Willis Lease’s compensation to Charles F. Willis, IV, represents excessive or wasteful compensation, and whether the Company’s board of directors, together with Charles F. Willis, IV (as the controlling shareholder) have breached their fiduciary duties to Willis Lease’s stockholders in connection with the compensation.

Click here for more information:


https://www.bfalaw.com/cases/willis-lease-investigation

What Can You Do?

If you are a current holder of Willis Lease Finance Corporation stock, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/willis-lease-investigation

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/willis-lease-investigation

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Tennant Company (NYSE:TNC) for potential violations of the federal securities laws.

If you invested in Tennant, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/tennant-company-class-action-lawsuit.

Key Details of the Tennant ($TNC) Class Action Investigation:

• Investigation Overview: Securities fraud related to Tennant’s implementation and rollout of its new, company-wide enterprise resource planning (“ERP”) system
• Stock Decline: February 24, 2026 – 23.4% Stock Drop
• Action: Contact BFA Law to discuss your rights

Why is Tennant Being Investigated for Securities Fraud?

Tennant manufactures industrial cleaning equipment, including large mechanical floor scrubbers and sweepers used in warehouses, retail stores, and other commercial facilities.

BFA is investigating whether Tennant made false and misleading statements to investors regarding the implementation and rollout of a large-scale ERP system. For instance, Tennant assured investors the project was “progressing as we’ve anticipated,” was “on time and on budget,” and that the launch of the ERP in its Asia-Pacific region had been “successful,” with Tennant stating it had “mitigated disruptions and stabilized operations.”

Why did Tennant’s Stock Drop?

On February 24, 2026, Tennant revealed that the rollout of its new ERP system in North America caused severe operational disruptions, including that it was unable to process and ship customer orders following the launch of the system. As a result, Tennant lost roughly $30 million in sales and would need to spend more than $20 million in 2026 to remediate the issues, compared to roughly $5 million the company had planned to spend.

This news caused the price of Tennant stock to drop $19.28 per share, more than 23%, from a closing price of $82.30 per share on February 23, 2026, to $63.02 per share on February 24, 2026.

Click here for more information:

https://www.bfalaw.com/cases/tennant-company-class-action-lawsuit

.

What Can You Do?

If you invested in Tennant, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/tennant-company-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/tennant-company-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RE/MAX Holdings, Inc.’s (NYSE: RMAX) board of directors as well as RE/MAX co-founder and chairman David Liniger. The investigation focuses on potential breaches of fiduciary duties to shareholders in connection with the pending merger between RE/MAX and The Real Brokerage Inc. announced on April 27, 2026.

If you are a current shareholder of RE/MAX, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/re-max-holdings-inc-investigation.

Why is RE/MAX being Investigated?

On April 27, 2026, RE/MAX Holdings, Inc. announced that it had agreed to be acquired by The Real Brokerage, Inc. in a deal where stockholders of RE/MAX can elect to receive either $13.80 in cash per share or 5.15 shares of the post-merger entity.

BFA Law is investigating whether the merger was executed at an unfairly low price and whether RE/MAX’s insiders are receiving potentially unfair benefits in the merger that are not shared with public stockholders who own RE/MAX’s stock.

Click here for more information:


https://www.bfalaw.com/cases/re-max-holdings-inc-investigation


.

What Can You Do?

If you are a current holder of RE/MAX Holdings, Inc. stock, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/re-max-holdings-inc-investigation

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/re-max-holdings-inc-investigation

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into PennyMac Financial Services, Inc. (NYSE:PFSI) for potential violations of the federal securities laws.

If you invested in PennyMac, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/pennymac-class-action-lawsuit.

Why is PennyMac Being Investigated for Violations of the Federal Securities Laws?

PennyMac originates and services home mortgages. Recently, PennyMac increased its capacity to originate loans to better retain borrowers seeking to refinance their mortgages—a process known as “recapture” —as interest rates declined. During the relevant period, PennyMac touted the success of its recapture efforts, representing to investors that its recapture rates were improving.

BFA is investigating whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages as interest rates declined.

Why did PennyMac’s Stock Drop?

On January 29, 2026, PennyMac reported disappointing 4Q 2025 financial results. During PennyMac’s earnings call held the same day, PennyMac senior management revealed that although PennyMac had increased its origination capacity to recapture more refinance business, many competitors had also added capacity, creating a highly competitive origination environment that constrained PennyMac’s ability to take advantage of refinance opportunities. This news caused the price of PennyMac stock to decline more than 37%, from $140.70 per share at the close of trading on January 29, 2026, to as low as $93.50 per share on January 30, 2026.

Click here for more information:

https://www.bfalaw.com/cases/pennymac-class-action-lawsuit

.

What Can You Do?

If you invested in PennyMac, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/pennymac-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/pennymac-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Simply Good Foods Company (NASDAQ:SMPL) for potential securities fraud after its significant stock drop.

If you invested in Simply Good Foods, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simply-good-foods-class-action-lawsuit.

Key Details of the Simply Good Foods ($SMPL) Class Action Investigation:

• Investigation Overview: Securities fraud related to Simply Good Foods’ protein product distribution expansion, product quality, and execution issues.
• Stock Decline: April 9, 2026 – 18.11% Stock Drop
• Action: Contact BFA Law to discuss your rights

Why is Simply Good Foods Being Investigated for Securities Fraud?

Simply Good Foods is a consumer packaged food and beverage company. The company’s products primarily consist of protein bars and ready-to-drink (“RTD”) protein shakes under the Quest and OWYN brand names. 

BFA is investigating whether Simply Good Foods made false and misleading statements to investors regarding the purported success of its initiative to expand distribution of its Quest and OWYN-branded protein products.

Why did Simply Good Foods’ Stock Drop?

On April 9, 2026, Simply Good Foods released its fiscal Q2 2026 financial results. The company announced net sales of $326 million, a 9.4% decline year-over-year, and cut 2026 guidance to a range of – 10% to – 7% year-over-year. During the corresponding earnings call, Simply Good Foods’ CEO stated that the company’s significant expansion of OWYN products experienced “a combination of a product quality issue . . . that impacted taste, texture and consumer acceptance and poor marketing execution [that] negatively impacted performance during the critical expansion window.” Simply Good Foods also revealed a $249 million impairment charge “largely the result of a challenging fiscal year 2026 and updated projections of future revenue.”

This news caused the price of Simply Good Foods stock to drop $2.61 per share, or more than 18%, from a closing price of $14.41 per share on April 8, 2026, to $11.80 per share on April 9, 2026.

Click here for more information:


https://www.bfalaw.com/cases/simply-good-foods-class-action-lawsuit


.

What Can You Do?

If you invested in Simply Good Foods, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/simply-good-foods-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/simply-good-foods-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ:MEDP) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Medpace, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medpace-class-action-lawsuit.

Key Details of the Medpace ($MEDP) Class Action:

• Lead Plaintiff Deadline: June 8, 2026
• Alleged Misconduct: Securities fraud regarding Medpace’s alleged understatement of cancellation rates and overstatement of book-to-bill ratio.
• Largest Alleged Stock Decline: February 9, 2026 – 15.9% Stock Drop
• Court: U.S. District Court for the Southern District of Ohio
• Action: Contact BFA Law to discuss your rights

Investors have until June 8, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Medpace common stock. The case is pending in the U.S. District Court for the Southern District of Ohio. It is captioned Durbin v. Medpace Holdings Inc., et al., No. 1:26-cv-00346.

Why is Medpace Being Sued For Securities Fraud?

Medpace is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.

During the relevant period, Medpace allegedly misled investors concerning its book-to-bill ratio for 4Q 25. According to Medpace, “our award notifications were strong. Cancellations were down across the pipeline.” Medpace also discussed how cancellations were “very well behaved.”

As alleged, in truth, Medpace’s cancellations had increased causing its book-to-bill ratio to decline.

Why did Medpace’s Stock Drop?

On February 9, 2026, Medpace released its 4Q 2025 financial results, reporting that its book-to-bill ratio declined to 1.04 due to elevated cancellations.

This news caused the price of Medpace stock to drop nearly 16%, from $530.35 per share on February 9, 2026 to 446.05 per share on February 10, 2026.

BFA is also investigating recent reports that Medpace’s cancellations continued to increase and book-to-bill ratio continued to decline, reaching as low as 0.88 for 1Q 26. The company’s President, Jesse Geiger, also announced his intention to resign.
  
On this news, the price of the company’s stock declined roughly 23% during afternoon trading on April 23, 2026.

Click here for more information:

https://www.bfalaw.com/cases/medpace-class-action-lawsuit

.

What Can You Do?

If you invested in Medpace, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/medpace-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/medpace-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.

If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

Why is ADMA Biologics Being Investigated for Securities Fraud?

ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics. ADMA Biologics’ flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.

BFA is investigating allegations that ADMA Biologics’ reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.

Why did ADMA Biologics’ Stock Drop?

On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.

This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.

Click here for more information:

https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit

.

What Can You Do?

If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

SOUTH BEND, Ind., May 08, 2026 (GLOBE NEWSWIRE) — Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) today announced that its Board of Directors declared a cash dividend on its common stock in the amount of $0.17 per share (the “Dividend”). The Dividend will be payable in cash on June 30, 2026, to stockholders of record as of the close of business on June 16, 2026.

About Strawberry Fields REIT

Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing and certain other healthcare-related properties. The Company’s portfolio includes 143 healthcare facilities with an aggregate of 15,600+ beds, located throughout the states of Arkansas, Illinois, Indiana, Kansas, Kentucky, Missouri, Ohio, Oklahoma, Tennessee and Texas. The 143 healthcare facilities comprise 131 skilled nursing facilities, 10 assisted living facilities, and two long-term acute care hospitals.

Safe Harbor Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.

Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the COVID-19 pandemic and the measures taken to prevent its spread and the related impact on our business or the businesses of our tenants; (ii) the ability and willingness of our tenants to meet and/or perform their obligations under the triple-net leases we have entered into with them, including, without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the ability of our tenants to comply with applicable laws, rules and regulations in the operation of the properties we lease to them; (iv) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (v) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities, and the ability to acquire and lease the respective properties to such tenants on favorable terms; (vi) the ability to generate sufficient cash flows to service our outstanding indebtedness; (vii) access to debt and equity capital markets; (viii) fluctuating interest rates; (ix) the ability to retain our key management personnel; (x) the ability to maintain our status as a real estate investment trust (“REIT”); (xi) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xii) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xiii) any additional factors included under “Risk Factors” in our Form 8-K filed with the SEC on April 14, 2026, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC.

Forward-looking statements speak only as of the date of this press release. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.

Investor Relations:

Strawberry Fields REIT, Inc.
[email protected]
+1 (773) 747-4100 x422